Eva‐Maria Fronk - Concepedia

Author

Eva‐Maria Fronk

Also Known As

E Fronk, E M Fronk, E. M. Fronk, E.-M. Fronk, E.M. Fronk, Eva-Maria Fronk, Eva‐Maria Fronk, Julio Lopez-Bastida, Petra Laeis, Rupert Bauersachs

Publications

535

Citations

H-Index

Concepts

All Affiliations

Daiichi Sankyo (Germany)Mahlo (Germany)IPPMed (Germany)Charité - Universitätsmedizin Berlin Guy's and St Thomas' NHS Foundation Trust

About

Eva‐Maria Fronk is an author at Daiichi Sankyo (Germany) specializing in medicine, cardiovascular disease, and patient safety.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	172
2	Emergency Medicine	3	3	124
3	Public Health	2	2	110
4	Epidemiology	2	2	110
5	Anesthesia	1	1	26

Eva‐Maria Fronk

Publications

392

Citations

H-Index

Page 1

	Year	Citations
Randomized, Double-Blind, Placebo-Controlled Study About the Effects of Cannabidiol (CBD) on the Pharmacokinetics of ??9-Tetrahydrocannabinol (THC) After Oral Application of THC Verses Standardized Cannabis Extract Thomas Nadulski, Fritz Pragst, Gordon Weinberg, Therapeutic Drug Monitoring	2005	179
The management of acute venous thromboembolism in clinical practice Alexander T. Cohen, Anselm K. Gitt, Rupert Bauersachs, Thrombosis and Haemostasis Recurrent VteHypertensionLogistic AnalysisThrombosisVenous Thrombosis	2017	83
Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE Michela Giustozzi, Luca Valerio, Giancarlo Agnelli, European Journal of Internal Medicine Clinical CoursePulmonary EmbolismThrombosisVenous ThrombosisBaseline Risk Factors	2021	27
Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Arndt Büssing, Mechtild Bischof, Wolfgang Hatzmann, PubMed Surgical OncologyImmunotoxicologySurgeryPharmacotherapyImmune System	2006	26
Clinical Impact of Patient Adherence to a Fixed-Dose Combination of Olmesartan, Amlodipine and Hydrochlorothiazide Peter Bramlage, Reinhard G. Ketelhut, Eva‐Maria Fronk, Clinical Drug Investigation Patient AdherenceNon-pharmacological InterventionPatient SafetyPharmacologyPharmacotherapy	2014	22
Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry Julio López‐Bastida, Isaac Aranda-Reneo, Beatriz Rodríguez-Sánchez, Orphanet Journal of Rare Diseases	2021	16
The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry Rupert Bauersachs, Giancarlo Agnelli, Anselm K. Gitt, Thrombosis Research ThrombosisVte RegistryReal-world ManagementVenous ThrombosisCardiovascular Disease	2017	14
Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice Peter Bramlage, Eva‐Maria Fronk, Wolf-Peter Wolf, Vascular Health and Risk Management	2014	13
Quality of life and emotional impact of a fixed‐dose combination of antihypertensive drugs in patients with uncontrolled hypertension Roland E. Schmieder, Agnes Jumar, Eva‐Maria Fronk, Journal of Clinical Hypertension	2016	12

Page 1